Corcept Therapeutics is trading 4.2% down now at $88.06, experiencing profit-taking after a recent rally. - The stock surged following news on July 11, 2026, of Corcept's plan to resubmit its New Drug Application to the FDA for relacorilant as a treatment for Cushing's syndrome, five months after the initial Complete Response Letter on December 31, 2025. - This decline follows earlier gains potentially driven by positive Phase 3 ROSELLA ovarian cancer data announced on January 22, 2026, and subsequent FDA approval in March 2026. - The broader biotech sector has shown strong momentum recently, suggesting today's move is primarily company-specific profit-taking.